Table 1.

Demographics and patient characteristics

Race, n (%)
Chinese	14 (73.7)
Malay	3 (15.8)
Others	2 (10.5)
Gender, n (%)
Male	16 (84.2)
Female	3 (15.8)
HAART use during RD, n (%)
Yes	18 (94.7)
No	1 (5.3)
Intravitreal Ganciclovir use, n (%)
Yes	18 (94.7)
No†	1 (5.3)
IRU before retinal detachment, n (%)
Yes	7 (36.8)
No	12 (63.2)
Mean age, years (SD)
HIV diagnosis	40.6 (7.34)
Retinal reattachment surgery	45.6 (9.35)
Median CD4 counts, cells /μL [Range]
HIV diagnosis	97.0 [2 - 830]
CMV retinitis diagnosis	53.0 [6 - 410]
Retinal detachment (RD)	91.5 [15 - 571]
Active CMVR at RD (n = 5)	67.0 [20 - 247]
Inactive CMVR at RD (n = 13)	93.0 [15 - 571]
Median intervals, months [Range]
HIV to RD	16.5 [3 - 210]
CMV retinitis to RD	2.7 [0 - 121]
HIV to commencement of HAART	14.6 [0 - 217]
Commencement of HAART to RD	9.0 [-1 - 112]
Immune recovery uveitis to RD	1.0 [0 - 12]

^†Received oral valganciclovir.

HAART: highly active anti-retroviral therapy, RD: retinal detachment, IRU: immune recovery uveitis, HIV: Human immunodeficiency virus, CMVR: cytomegalovirus retinitis.